Jetrea ocriplasmin regulatory update

ThromboGenics said Uruguay and Singapore approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated with macular hole diameter of <=400 Ug. The company said Uruguay is the first country in Latin America to approve the drug. Jetrea is approved in the U.S. to treat symptomatic vitreomacular adhesion (VMA) and in the EU to treat VMT (see BioCentury, March 3). The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has ex-U.S. commercialization rights to Jetrea, which is recombinant microplasmin, a truncated form of the natural human protein plasmin. ...